Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

Tolani, 2018, Heterogeneous contributing factors in MPM disease development and progression: biological advances and clinical implications, Int J Mol Sci, 19, 238, 10.3390/ijms19010238

Baas, 2015, Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 26, v31, 10.1093/annonc/mdv199

Green, 2007, Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma, Cochrane Database Syst Rev, 1

Song, 2020, Taken together: effective multimodal approaches for malignant pleural mesothelioma, Thorac Surg Clin, 30, 481, 10.1016/j.thorsurg.2020.08.002

Reuss, 2020, Immunotherapy for mesothelioma: rationale and new approaches, Clin Adv Hematol Oncol, 18, 562

Scagliotti, 2019, Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial, Lancet Respir Med, 7, 569, 10.1016/S2213-2600(19)30139-0

Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136

Zalcman, 2016, Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial, Lancet, 387, 1405, 10.1016/S0140-6736(15)01238-6

Petrelli, 2018, A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma, Respir Med, 141, 72, 10.1016/j.rmed.2018.06.026

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239

Cedres, 2015, Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM), PLoS One, 10, 10.1371/journal.pone.0121071

Chapel, 2019, Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28–8 pharmDx assays, Hum Pathol, 87, 11, 10.1016/j.humpath.2019.02.001

Mansfield, 2014, B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis, J Thorac Oncol, 9, 1036, 10.1097/JTO.0000000000000177

Ott, 2019, T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028, J Clin Oncol, 37, 318, 10.1200/JCO.2018.78.2276

Alley, 2017, Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial, Lancet Oncol, 18, 623, 10.1016/S1470-2045(17)30169-9

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Desai A, Karrison P, Rose B, et al. Phase II trial of pembrolizumab (NCT02399371) in previously treated malignant mesothelioma: final analysis. IASLC 19th World Conference on Lung Cancer 2018; Toronto, Canada; Sept 23–26, 2018 (abstr 8565).

Popat, 2020, A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9–15) PROMISE-meso trial, Ann Oncol, 31, 1734, 10.1016/j.annonc.2020.09.009

Okada, 2019, Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT), Clin Cancer Res, 25, 5485, 10.1158/1078-0432.CCR-19-0103

Quispel-Janssen, 2018, Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma, J Thorac Oncol, 13, 1569, 10.1016/j.jtho.2018.05.038

Hassan, 2019, Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial, JAMA Oncol, 5, 351, 10.1001/jamaoncol.2018.5428

Scherpereel, 2019, Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial, Lancet Oncol, 20, 239, 10.1016/S1470-2045(18)30765-4

Calabro, 2018, Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study, Lancet Respir Med, 6, 451, 10.1016/S2213-2600(18)30151-6

Disselhorst, 2019, Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial, Lancet Respir Med, 7, 260, 10.1016/S2213-2600(18)30420-X

Baas, 2020, ID:2908 First-line nivolumab + ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743, J Thorac Oncol, 15, E42, 10.1016/j.jtho.2020.08.004

Mandrekar, 2010, Randomized phase II trials: time for a new era in clinical trial design, J Thorac Oncol, 5, 932, 10.1097/JTO.0b013e3181e2eadf

Marabelle, 2020, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, Lancet Oncol, 21, 1353, 10.1016/S1470-2045(20)30445-9

Steiniche, 2020, Association of programmed death ligand 1 expression with prognosis among patients with 10 uncommon advanced cancers, Future Sci OA, 6, 10.2144/fsoa-2020-0063